Adipose-derived stem cells induced EMT-like changes in H358 lung cancer cells.
Park YM., Yoo SH., Kim SH.
Laboratory Study, published in Anticancer Res (2013) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Anticancer Res (2013)
- Country
- Greece
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 24123011
- Citations
- 30
Abstract (original English)
Despite the potential utility of adipose-derived mesenchymal stem cells (ADSCs) in regenerative medicine, not much is known about their interaction with residual cancer cells. Here, we studied the direct co-culture effects of ADSCs on H358 lung cancer cells. The paracrine effects of ADSCs were compared to those of the cancer-associated fibroblasts. Extracellular matrix and conditioned media were used to determine the underlying molecules. Time-lapse photography, fluorescence-activated cell sorting (FACS), scratch assays, immunocytochemistry, and reverse-transcription polymerase chain reaction were used to analyze the effects. ADSCs differentiated into myofibroblasts expressing αSMA, and H358 cells strongly attached to them. EMT-like changes were observed in H358 cells which were inhibited by γ-secretase inhibitor, a-NOTCH inhibitor. Surprisingly, both mesenchymal and epithelial genes were expressed, and the effects were readily reversed when cells were sorted by FACS. These data suggest that ADSCs may differentiate into tumor stroma that plays supportive roles during cancer progression.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.